Identifying key tumor- and immune-centric parameters using streamlined single cell workflows to help guide the development and validation of engineered TCR-T cells for cancer.
Single-cell analysis of bispecific CD20/CD19 CAR-T cells to identify CAR T cells with favorable anti-tumor killing potential.
A better understanding of the target specificity and biological properties of T cells that correlate with clinical outcomes is needed to help guide the development and manufacturing of highly efficacious CAR-T/TCR-T cells.
